Pfizer director acquires 1,570 deferred stock units
The director's deferred compensation is settled in cash or common stock at his election following retirement from the Board of Directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pfizer Inc. director James C. Smith acquired 1,569.585 Phantom Stock Units on September 25, 2026, as deferred director's compensation, including dividend equivalents. Each unit represents one phantom share of common stock, and his reported position after the acquisition was 187,210.086 Phantom Stock Units. Following retirement from the Board of Directors, Smith may elect settlement in cash or common stock.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock Units F1, F2 | 1,569.585 | $28.67 | $45K |
Footnotes (2)
- F1. Each unit represents one phantom share of common stock.
- F2. These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.
Key Figures
Key Terms
Phantom Stock Units financial
dividend equivalents financial
deferred director's compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many PFE Phantom Stock Units did director James C. Smith acquire?
How are PFE director James C. Smith's Phantom Stock Units settled?
AI-generated analysis. How Rhea-AI works. Not financial advice.